Biogen's Alzheimer's Drug Failed Its Test. They're Betting Billions Anyway.

The Tau Connection Nobody Can Ignore

What really caught researchers' attention wasn't just the cognitive scores. It was what happened inside patients' brains.

A quick primer: Alzheimer's involves two rogue proteins. Amyloid forms plaques between brain cells. Tau forms tangles inside them. Most approved Alzheimer's drugs target amyloid. Diranersen goes after tau, and it does so in a fundamentally different way than anything that's come before.

Diranersen is an antisense oligonucleotide (ASO), which is a fancy term for a synthetic strand of genetic material that intercepts tau's blueprint before the protein ever gets made. While antibody drugs try to mop up tau after it's already floating around, diranersen shuts off the faucet at the source. It reduces all forms of tau, both inside and outside neurons.

The results on that front were striking. Patients on diranersen saw their spinal fluid tau levels drop by 50 to 65% across all doses. Brain scans using tau PET imaging confirmed the protein was declining across multiple brain regions, too. Those reductions held steady throughout the entire 18-month treatment period.

Biogen calls this "unprecedented," and that's not just marketing spin. No other tau-targeting drug has ever shown reductions this large in a randomized, controlled trial while also producing measurable cognitive benefits. The correlation between tau reduction and slower cognitive decline strengthens the case that tau isn't just a bystander in Alzheimer's; it's a driver.

The Billion-Dollar Bet

So why is Biogen pressing forward despite the technical miss? Because the totality of the data tells a more compelling story than the primary endpoint alone.

Every dose beat placebo on the key dementia scale. The biomarker data showed massive, consistent tau reduction. And the lowest dose produced cognitive benefits roughly comparable in magnitude to approved anti-amyloid therapies, according to analysts who've reviewed the data (with the usual caveats about cross-trial comparisons).

Wall Street is coming around to this view, even after the initial selloff. Oppenheimer raised its target to $300. Wolfe Research called the results the first real proof-of-concept for tau-targeted therapy in Alzheimer's, noting that Biogen's decision to advance the program signals strong internal confidence in the data.

The Alzheimer's Association, which hosted the data presentation at its international conference (AAIC), described the results as "important progress."

The Regulatory Tightrope

Biogen's path forward raises a question the entire Alzheimer's field has been wrestling with: can strong biomarker data justify approval if the clinical results are imperfect?

There's precedent. Aducanumab (Biogen's earlier Alzheimer's drug) won accelerated approval largely on the strength of amyloid reduction, despite highly debated clinical results. The FDA's own guidance says that a biomarker "reasonably likely to predict clinical benefit" can support accelerated approval. But no Alzheimer's biomarker, including tau, has earned formal status as a validated surrogate endpoint.

Diranersen does have one regulatory advantage: FDA Fast Track designation, which can speed up development and review. And Biogen will almost certainly build Phase 3 around the 60 mg dose that showed the clearest benefit, eliminating the dose-response design that tripped them up in Phase 2.

Still, critics will point out that several Alzheimer's drugs have shown beautiful biomarker effects in mid-stage trials, only to fail when tested in larger, longer studies. The biomarker-to-clinic gap remains real.

Why This Matters Beyond Biogen

The bigger story here isn't about one company or one drug. It's about whether the Alzheimer's field can move beyond its amyloid obsession.

Tau-targeting therapies now make up roughly 20% of the Alzheimer's pipeline, matching amyloid-targeted programs for the first time. Other tau antibodies from Bristol Myers Squibb and others are in mid-stage trials with readouts expected over the next couple of years. But diranersen's ASO approach is unique in the field, going after tau production rather than tau cleanup.

If Biogen's Phase 3 succeeds, it won't just validate one drug. It will validate an entirely new therapeutic strategy for a disease that affects over 55 million people worldwide when all forms of dementia are included. And it will prove that the protein most closely linked to neurodegeneration (tau tangles correlate with cognitive decline far better than amyloid plaques) is a viable drug target.

That's a pretty good reason to sign up for next semester.

The FDA Wants to Build Drug Factories Inside Hospitals

The FDA proposed a new rule that could let drug manufacturers register entire networks of modular production units as a single facility. For cell and gene therapies, it's the regulatory foundation for a future where your cancer treatment gets made down the hall, not across the country.